Iskalni niz:
išči po
išči po
išči po
išči po
Vrsta gradiva:
Jezik:
Št. zadetkov: 3
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs
Romain Aymon, Denis Mongin, Romain Guemara, Zubeyir Salis, Johan Askling, Denis Choquette, Catalin Codreanu, Daniela Di Giuseppe, Irini Flouri, Doreen Huschek, Žiga Rotar
Izvirni znanstveni članek
Oznake: adverse cardiovascular events;rheumatoid arthritis;patients;Janus kinase inhibitors;biologic disease-modifying antirheumatic drugs;"JAK-pot" study;
Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs
Leto: 2025 Vir: Repozitorij Univerze v Ljubljani (RUL)
Evolution of Janus Kinase inhibitors (JAKi) prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)
Denis Mongin, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Sella A Provan, Tore K. Kvien, Ruth Fritsch-Stork, Dan C. Nordström, Žiga Rotar
Izvirni znanstveni članek
Oznake: drug safety regulation;Janus kinase inhibitors;registry;rheumatoid arthritis;drug prescription;
Background: Janus kinase inhibitors (JAKi) are effective for treating rheumatoid arthritis (RA), but post-marketing safety concerns have triggered regulatory warnings and updated guidelines. The impact of these communications on real-world prescribing remains unclear. Objectives: To assess the impac ...
Leto: 2026 Vir: Medicinska fakulteta (UL MF)
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)
Romain Aymon, Romain Aymon, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, Diederik De Cock, Lene Dreyer, Ori Elkayam, Doreen Huschek, Žiga Rotar
Izvirni znanstveni članek
Oznake: antirheumatic agents;arthritis, rheumatoid;biological therapy;epidemiology;
Background: In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis factor inhibitors (TNFi) adalimumab or etanercept. Objective: Compare treatmen ...
Leto: 2023 Vir: Repozitorij Univerze v Ljubljani (RUL)
Št. zadetkov: 3
Ključne besede:
Leto izdaje:
Avtorji:
Repozitorij:
Tipologija:
Jezik: